Tubulocystic renal cell carcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:319325C64
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Tubulocystic renal cell carcinoma (TC-RCC) is a very rare type of kidney cancer. It was officially recognized as a distinct subtype of renal cell carcinoma in 2013 by the International Society of Urological Pathology. This cancer gets its name from the way it looks under a microscope — it forms small tubes (tubules) and cysts lined by specific types of cells. The tumor typically appears as a sponge-like mass in the kidney, often made up of many small cysts of varying sizes. Most people with tubulocystic renal cell carcinoma do not have symptoms in the early stages. The tumor is often found by accident during imaging tests done for other reasons. When symptoms do occur, they may include blood in the urine, pain in the side or back, or a mass that can be felt in the abdomen. Compared to many other kidney cancers, TC-RCC tends to behave in a less aggressive manner, though rare cases of spread (metastasis) to other organs have been reported. Treatment usually involves surgery to remove the tumor, either by removing the entire kidney (radical nephrectomy) or just the part of the kidney containing the tumor (partial nephrectomy). Because this cancer is so rare, there are no large clinical trials specifically for TC-RCC, and treatment decisions are often guided by experience with other types of renal cell carcinoma. The overall outlook for most patients is favorable, especially when the cancer is caught early and has not spread beyond the kidney.

Also known as:

Key symptoms:

Blood in the urine (hematuria)Pain in the side or flank areaA lump or mass felt in the abdomenBack pain near the kidney areaUnexplained weight lossFatigue or tirednessNo symptoms at all (found incidentally on imaging)

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Tubulocystic renal cell carcinoma.

View clinical trials →

No actively recruiting trials found for Tubulocystic renal cell carcinoma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Tubulocystic renal cell carcinoma community →

No specialists are currently listed for Tubulocystic renal cell carcinoma.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Tubulocystic renal cell carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Tubulocystic renal cell carcinomaForum →

No community posts yet. Be the first to share your experience with Tubulocystic renal cell carcinoma.

Start the conversation →

Latest news about Tubulocystic renal cell carcinoma

No recent news articles for Tubulocystic renal cell carcinoma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my tubulocystic renal cell carcinoma, and has it spread beyond the kidney?,Is a partial nephrectomy (kidney-sparing surgery) an option for me, or do I need the whole kidney removed?,How often will I need follow-up imaging after surgery, and for how long?,Are there any clinical trials or newer treatments that might be relevant for my specific case?,What should I watch for that might indicate the cancer has come back?,Will losing part or all of a kidney affect my long-term health or kidney function?,Should I be tested for any hereditary kidney cancer syndromes given my diagnosis?

Common questions about Tubulocystic renal cell carcinoma

What is Tubulocystic renal cell carcinoma?

Tubulocystic renal cell carcinoma (TC-RCC) is a very rare type of kidney cancer. It was officially recognized as a distinct subtype of renal cell carcinoma in 2013 by the International Society of Urological Pathology. This cancer gets its name from the way it looks under a microscope — it forms small tubes (tubules) and cysts lined by specific types of cells. The tumor typically appears as a sponge-like mass in the kidney, often made up of many small cysts of varying sizes. Most people with tubulocystic renal cell carcinoma do not have symptoms in the early stages. The tumor is often found by

How is Tubulocystic renal cell carcinoma inherited?

Tubulocystic renal cell carcinoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Tubulocystic renal cell carcinoma typically begin?

Typical onset of Tubulocystic renal cell carcinoma is adult. Age of onset can vary across affected individuals.